上海醫藥(02607.HK)擬成立投資基金 參與醫療產業鏈戰略佈局
格隆匯 10 月 29日丨上海醫藥(02607.HK)公告,於2020年10月29日,公司訂立合夥協議,內容有關設立預期規模為人民幣90億元,且首期認購結束時規模為人民幣70億元的投資基金,據此,公司(作為有限合夥人)、上海上實(作為有限合夥人)、國泰君安母基金(作為有限合夥人)、臨港投資(作為有限合夥人)、國際集團(作為有限合夥人)、長寧投資(作為有限合夥人)、上海上投(作為有限合夥人)及上海生物醫藥產業基金(作為普通合夥人)已分別同意認購人民幣15億元、人民幣20億元、人民幣14億元、人民幣10億元、人民幣5億元、人民幣5億元、人民幣0.5億元及人民幣0.5億元的投資基金份額。
名稱上海生物醫藥產業股權投資基金合夥企業(有限合夥)(暫定名)。
通過訂立合夥協議成立投資基金,公司不僅可以獲取合理投資收益,還將與投資基金進行多方面的戰略合作併發揮協同作用,通過參與醫療產業鏈中創新企業的孵化與培育優化公司的戰略佈局。成立投資基金亦有利於擴大公司對私募基金行業的影響力及品牌效應,並吸引更多優質項目資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.